The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX.
Patrick W SerruysNorihiro KogameRodrigo ModoloKuniaki TakahashiRutao WangHideyuki KawashimaMasafumi OnoHironori HaraMariusz TomaniakAzfar ZamanRobbert J de WinterRobert-Jan van GeunsUpendra KaulPatrick W SerruysYoshinobu OnumaPublished in: Future cardiology (2020)
Percutaneous coronary interventions with drug-eluting stents is currently the preferred revascularization treatment strategy for coronary artery disease. Following the first generation, the second-generation drug-eluting stents was designed with a thinner strut, better biocompatible polymer with/without bioresorbable coating or even polymer-free struts. The SUPRAFLEX stent system has ultra-thin struts (60 μm) across all stent diameters and a biodegradable polymer coating, enabling 70% of the sirolimus elution within 7 days. SUPRAFLEX has been assessed in large scale randomized controlled trials. This review summarizes the design of the SUPRAFLEX stent, the results of the pivotal clinical trials and outlines the ongoing research programs.
Keyphrases
- coronary artery disease
- clinical trial
- percutaneous coronary intervention
- coronary artery
- coronary artery bypass grafting
- randomized controlled trial
- high resolution
- cardiovascular events
- physical activity
- drug delivery
- public health
- minimally invasive
- heart failure
- systematic review
- adverse drug
- mass spectrometry
- combination therapy
- acute coronary syndrome
- phase iii
- meta analyses
- smoking cessation